Re: Post-progression outcomes of NSCLC patients with PD-L1 expression >= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

SÜTCÜOĞLU O., ÖZDEMİR N., YAZICI O.

EUROPEAN JOURNAL OF CANCER, vol.155, pp.294-295, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 155
  • Publication Date: 2021
  • Doi Number: 10.1016/j.ejca.2021.07.005
  • Journal Name: EUROPEAN JOURNAL OF CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.294-295
  • Gazi University Affiliated: Yes